Cargando…

Real-world drug survival of patients with hidradenitis suppurativa treated with adalimumab

Detalles Bibliográficos
Autores principales:	Saal, Ryan C., Alnaif, Sarah, Edwards, Joshua F., Wintringham, Jennifer A., Smith, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149381/ https://www.ncbi.nlm.nih.gov/pubmed/37138828 http://dx.doi.org/10.1016/j.jdin.2023.03.004

Ejemplares similares

Optic neuropathy in a patient treated with adalimumab for hidradenitis suppurativa
por: Alnaif, Sarah, et al.
Publicado: (2023)

Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real‐world results from the HARMONY Study
por: Hafner, A., et al.
Publicado: (2021)

Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab
por: Gorovoy, Ian, et al.
Publicado: (2009)

Hidradenitis suppurativa and adalimumab in the COVID-19 era
por: Marzano, Angelo Valerio, et al.
Publicado: (2021)

Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data
por: Kyriakou, Aikaterini, et al.
Publicado: (2018)

Real‐world effectiveness of adalimumab in patients with moderate‐to‐severe hidradenitis suppurativa: the 1‐year SOLACE study
por: Gulliver, W., et al.
Publicado: (2021)

Two Cases of Paradoxical Hidradenitis Suppurativa while on Adalimumab
por: Harvin, Glenn, et al.
Publicado: (2016)

Treatment of Hidradenitis Suppurativa Patient with Klinefelter Syndrome by Adalimumab
por: Shin, Ji Yeoun, et al.
Publicado: (2019)

Adalimumab-Induced Thrombocytopenia in a Patient With Hidradenitis Suppurativa
por: Al-Tkrit, Amna, et al.
Publicado: (2021)

ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
por: Craig, Alexander, et al.
Publicado: (2023)

Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience
por: CHIRICOZZI, Andrea, et al.
Publicado: (2020)

Metastatic squamous cell carcinoma in a patient treated with adalimumab for hidradenitis suppurativa
por: Giesey, Rachel, et al.
Publicado: (2017)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
por: Martora, Fabrizio, et al.
Publicado: (2023)

Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa
por: Fotiadou, Christina, et al.
Publicado: (2016)

Genital lymphedema associated with hidradenitis suppurativa unresponsive to adalimumab treatment
por: Musumeci, Maria Letizia, et al.
Publicado: (2019)

A complication in a patient with hidradenitis suppurativa taking adalimumab
por: Perez, Olivia D., et al.
Publicado: (2022)

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study
por: Prens, L.M., et al.
Publicado: (2021)

Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab
por: Bosnić, Dubravka, et al.
Publicado: (2016)

The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa
por: Frew, John W., et al.
Publicado: (2021)

Paradoxical Reaction in a Patient with Hidradenitis Suppurativa Undergoing Adalimumab Treatment
por: IKEYA, Soichiro, et al.
Publicado: (2021)

Treating hidradenitis suppurativa patients with adalimumab: a real-life experience of a tertiary care center in Lisboa, Portugal()
por: Neves, José Miguel, et al.
Publicado: (2022)

Real‐world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12‐week interim analysis of post‐marketing surveillance in Japan
por: Hayashi, Nobukazu, et al.
Publicado: (2022)

Certolizumab to treat hidradenitis suppurativa
por: Shadid, Asem, et al.
Publicado: (2022)

Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
por: Kearns, Donovan G., et al.
Publicado: (2020)

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis
por: Alam, Maryam Shayesteh, et al.
Publicado: (2020)

Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations
por: Blaszczak, Alecia, et al.
Publicado: (2020)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
por: Montero-Vilchez, Trinidad, et al.
Publicado: (2022)

Adalimumab Effect on Pain in Hidradenitis Suppurativa Patients: Systematic Review and Meta-Analysis
por: Tsentemeidou, Aikaterini, et al.
Publicado: (2022)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
por: Burlando, Martina, et al.
Publicado: (2022)

Adalimumab for the Treatment of Periodontitis in a 35-Year-Old Woman with Hidradenitis Suppurativa
por: Yao, Yiqiu, et al.
Publicado: (2023)

Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real‐life experience and therapeutic response to other biological drugs
por: Burzi, Lorenza, et al.
Publicado: (2022)

Coexistence of Hidradenitis Suppurativa and Steatocystoma Multiplex: Is It a New Variant of Hidradenitis Suppurativa?
por: Fletcher, Joshua, et al.
Publicado: (2021)

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study
por: REPETTO, Federica, et al.
Publicado: (2023)

Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study
por: Bouwman, Klasiena, et al.
Publicado: (2022)

Hidradenitis suppurativa with SAPHO syndrome maintained effectively with adalimumab, methotrexate, and intralesional corticosteroid injections
por: Crowley, Erika L, et al.
Publicado: (2018)

Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn’s Disease?
por: Beraldo, Rodrigo Fedatto, et al.
Publicado: (2020)

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa
por: Tatian, Artiene, et al.
Publicado: (2022)

IgA Vasculitis With Adalimumab Therapy for Hidradenitis Suppurativa: A Case Report and Review of Literature
por: Alsulami, Sarah, et al.
Publicado: (2022)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis
por: Ryan, Caitriona, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vl8pg2bip9u2v3a1ocj5f3p389